- Home
- GITS vs IMNN Comparison
GITS vs IMNN Comparison
Compare GITS & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GITS
- IMNN
- Stock Information
- Founded
- GITS 2018
- IMNN 1982
- Country
- GITS South Korea
- IMNN United States
- Employees
- GITS N/A
- IMNN N/A
- Industry
- GITS
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- GITS
- IMNN Health Care
- Exchange
- GITS Nasdaq
- IMNN Nasdaq
- Market Cap
- GITS 11.6M
- IMNN 13.8M
- IPO Year
- GITS N/A
- IMNN 1985
- Fundamental
- Price
- GITS $0.17
- IMNN $0.89
- Analyst Decision
- GITS
- IMNN Strong Buy
- Analyst Count
- GITS 0
- IMNN 2
- Target Price
- GITS N/A
- IMNN $20.50
- AVG Volume (30 Days)
- GITS 735.5K
- IMNN 426.8K
- Earning Date
- GITS 11-20-2024
- IMNN 11-07-2024
- Dividend Yield
- GITS N/A
- IMNN N/A
- EPS Growth
- GITS N/A
- IMNN N/A
- EPS
- GITS N/A
- IMNN N/A
- Revenue
- GITS N/A
- IMNN N/A
- Revenue This Year
- GITS N/A
- IMNN N/A
- Revenue Next Year
- GITS N/A
- IMNN N/A
- P/E Ratio
- GITS N/A
- IMNN N/A
- Revenue Growth
- GITS 85.47
- IMNN N/A
- 52 Week Low
- GITS $0.17
- IMNN $0.48
- 52 Week High
- GITS $0.75
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- GITS N/A
- IMNN 49.72
- Support Level
- GITS N/A
- IMNN $0.84
- Resistance Level
- GITS N/A
- IMNN $1.08
- Average True Range (ATR)
- GITS 0.00
- IMNN 0.07
- MACD
- GITS 0.00
- IMNN -0.01
- Stochastic Oscillator
- GITS 0.00
- IMNN 27.00
About GITS Global Interactive Technologies Inc. Common Stock
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About IMNN Imunon Inc.
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.